Skip to main content
. 2022 May 13;40(10):2381–2386. doi: 10.1007/s00345-022-04015-1

Table 2.

First line options which are considered standard of care

Recommendations Level of Evidence (LoE) Grade of recommendation Grade of consensus
Offer axitinib + pembrolizumab to treatment-naïve patients with any IMDC-risk category 1 − A Strong
Physicians may offer axitinib + avelumab to treatment-naïve patients with any IMDC-risk category 1 − B Consensus
Offer ipilimumab + nivolumab to treatment-naïve patients with intermediate or poor IMDC-risk category 1 − A Strong